Lifesci Capital Issues Positive Forecast for ELVN Earnings

Key Points

• Lifesci Capital has raised its Q3 2025 earnings per share (EPS) estimate for Enliven Therapeutics to ($0.45), improving from a prior forecast of ($0.52).
• Several equities research analysts have given Enliven Therapeutics a consensus rating of "Buy" with target prices ranging from $27.00 to $52.00.
• Institutional investors hold a significant stake in Enliven Therapeutics, owning over 95% of the company's stock, highlighting strong institutional interest.

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) - Equities researchers at Lifesci Capital increased their Q3 2025 earnings per share estimates for shares of Enliven Therapeutics in a report released on Thursday, August 14th. Lifesci Capital analyst S. Slutsky now expects that the company will earn ($0.45) per share for the quarter, up from their previous forecast of ($0.52). The consensus estimate for Enliven Therapeutics' current full-year earnings is ($1.95) per share. Lifesci Capital also issued estimates for Enliven Therapeutics' Q4 2025 earnings at ($0.47) EPS and FY2025 earnings at ($1.96) EPS.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last announced its earnings results on Wednesday, August 13th. The company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.04.

Other research analysts also recently issued reports about the company. The Goldman Sachs Group started coverage on Enliven Therapeutics in a research note on Monday, June 16th. They set a "buy" rating and a $37.00 target price for the company. Jones Trading reduced their target price on Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating for the company in a research note on Friday, May 16th. HC Wainwright lifted their price target on Enliven Therapeutics from $40.00 to $48.00 and gave the stock a "buy" rating in a research note on Wednesday, July 2nd. Finally, Robert W. Baird lifted their price target on Enliven Therapeutics from $40.00 to $52.00 and gave the stock an "outperform" rating in a research note on Monday, June 16th. Five analysts have rated the stock with a Buy rating, According to MarketBeat.com, Enliven Therapeutics presently has an average rating of "Buy" and an average price target of $41.20.

Enliven Therapeutics Stock Up 5.1%

Shares of ELVN stock traded up $1.01 during trading hours on Monday, hitting $20.85. 830,394 shares of the company's stock were exchanged, compared to its average volume of 362,165. The firm has a market cap of $1.24 billion, a P/E ratio of -10.43 and a beta of 0.93. The firm has a 50 day moving average of $20.61 and a two-hundred day moving average of $19.87. Enliven Therapeutics has a fifty-two week low of $13.30 and a fifty-two week high of $30.03.

Insider Buying and Selling

In related news, insider Joseph P. Lyssikatos sold 7,500 shares of the stock in a transaction that occurred on Thursday, August 21st. The stock was sold at an average price of $20.01, for a total value of $150,075.00. Following the completion of the sale, the insider owned 940,188 shares of the company's stock, valued at approximately $18,813,161.88. This trade represents a 0.79% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Benjamin Hohl sold 3,250 shares of the stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $20.46, for a total value of $66,495.00. Following the completion of the sale, the chief financial officer directly owned 23,000 shares of the company's stock, valued at approximately $470,580. This represents a 12.38% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 119,234 shares of company stock worth $2,472,368 in the last three months. Company insiders own 25.90% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC lifted its holdings in Enliven Therapeutics by 230.2% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company's stock valued at $36,000 after acquiring an additional 1,114 shares during the last quarter. GAMMA Investing LLC lifted its holdings in Enliven Therapeutics by 3,058.1% in the first quarter. GAMMA Investing LLC now owns 2,716 shares of the company's stock valued at $53,000 after acquiring an additional 2,630 shares during the last quarter. Quantbot Technologies LP acquired a new position in Enliven Therapeutics in the first quarter valued at approximately $60,000. BNP Paribas Financial Markets lifted its holdings in Enliven Therapeutics by 33.3% in the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company's stock valued at $75,000 after acquiring an additional 930 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its holdings in Enliven Therapeutics by 194.3% in the second quarter. Tower Research Capital LLC TRC now owns 5,286 shares of the company's stock valued at $106,000 after acquiring an additional 3,490 shares during the last quarter. 95.08% of the stock is currently owned by institutional investors and hedge funds.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.